Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population

References

• Centers for Disease Control and Prevention (CDC), Wheaton AG, Cunningham TJ, Ford ES, et al. Employment and activity limitations among adults with chronic obstructive pulmonary disease–United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(11):289–295.
   PubMed Web of Science ®Google Scholar
• Murphy SL, Xu J, Kochanek KD, et al. Mortality in the United States, 2017. NCHS Data Brief. 2018;328:1–8.
   Google Scholar
• Shah CH, Reed RM, Villalonga-Olives E, et al. Quantifying heterogeneity of physical and mental health-related quality of life in chronic obstructive pulmonary disease patients in the United States. Expert Rev Respir Med. 2020;14(9):937–947.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Li S, Eakin MN, et al. Projecting Long-term Health and Economic Burden of COPD in the United States. CHEST. 2021;159(4):1400–1410.
   PubMed Web of Science ®Google Scholar
• Müllerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Farmer SG. Exacerbations and progression of disease in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2004;1(2):88–92.
   PubMedGoogle Scholar
• Perera PN, Armstrong EP, Sherrill DL, et al. Acute Exacerbations of COPD in the United States: inpatient Burden and Predictors of Costs and Mortality. COPD. 2012;9(2):131–141.
   PubMedGoogle Scholar
• Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228.
   PubMedGoogle Scholar
• Schwab P, Dhamane AD, Hopson SD, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735–744.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LEGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735.
   PubMed Web of Science ®Google Scholar
• King PT. Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med. 2015;4. DOI:https://doi.org/10.1186/s40169-015-0068-z
   Google Scholar
• Yin H, Yin S, Lin Q, et al. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine (Baltimore). 2017;96(19):e6836.
   PubMed Web of Science ®Google Scholar
• Mannino DM, Higuchi K, Yu T-C, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138–150.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dutro MP, Marton JP, et al. Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data. BMC Health Serv Res. 2011;11(1):43.
   PubMedGoogle Scholar
• Bollu V, Guérin A, Gauthier G, et al. Readmission risk in chronic obstructive pulmonary disease patients: comparative study of nebulized β2-agonists. Drugs Real World Outcomes. 2016;4(1):33–41.
   Google Scholar
• COPD | National Heart, Lung, and Blood Institute (NHLBI). n.d. [cited 2020 Feb 16]. Available from: https://www.nhlbi.nih.gov/health-topics/copd
   Google Scholar
• Spece LJ, Epler EM, Donovan LM, et al. Role of comorbidities in treatment and outcomes after chronic obstructive pulmonary disease exacerbations. Ann Am Thorac Soc. 2018;15(9):1033–1038.
   PubMed Web of Science ®Google Scholar
• 30-day death and readmission measures data. n.d. [cited 2020 Apr 20]. Available from: https://www.medicare.gov/hospitalcompare/Data/30-day-measures.html
   Google Scholar
• Centers for Medicare and Medicaid Services. Hospital Readmissions Reduction Program (HRRP). 2019 Jul 31. [cited 2019 Sept 16]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.html
   Google Scholar
• Guerrero M, Crisafulli E, Liapikou A, et al. Readmission for acute exacerbation within 30 days of discharge is associated with a subsequent progressive increase in mortality risk in COPD patients: a long-term observational study. PLOS ONE. 2016;11(3):e0150737.
   PubMed Web of Science ®Google Scholar
• Viniol C, Vogelmeier CF. Exacerbations of COPD. Eur Respir Rev. 2018;27(147):147.
   Web of Science ®Google Scholar
• National Health Expenditure Accounts: methodology Paper, 2019. 2019. 44.
   Google Scholar
• Agency for Healthcare Research and Quality, Rockville, Md. HCUP CCS. Healthcare Cost and Utilization Project (HCUP). n.d. Available from: www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
   Google Scholar
• Hakim MA, Garden FL, Jennings MD, et al. Performance of the LACE index to predict 30-day hospital readmissions in patients with chronic obstructive pulmonary disease. Clin Epidemiol. 2018;10:51–59.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal T, Jeffries DJ, et al. Effect of temperature on lung function and symptoms in chronic obstructive pulmonary disease. Eur Respir J. 1999;13(4):844.
   PubMed Web of Science ®Google Scholar
• Gump DW, Phillips CA, Forsyth BR, et al. Role of infection in chronic bronchitis. Am Rev Respir Dis. 1976;113(4):465–474.
   PubMed Web of Science ®Google Scholar
• Bartels W, Adamson S, Leung L, et al. Emergency department management of acute exacerbations of chronic obstructive pulmonary disease: factors predicting readmission. Int J Chron Obstruct Pulmon Dis. 2018;13:1647–1654.
   PubMed Web of Science ®Google Scholar
• McHugh ML. The Chi-square test of independence. Biochem Med (Zagreb). 2013;23(2):143–149.
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Bergtold J, Jain R. A primer on marginal effects–Part I: theory and formulae. PharmacoEconomics. 2015;33(1):25–30.
   PubMed Web of Science ®Google Scholar
• Onukwugha E, Bergtold J, Jain R. A primer on marginal effects-part II: health services research applications. PharmacoEconomics. 2015;33(2):97–103.
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648.
   PubMed Web of Science ®Google Scholar
• Zafari Z, Sin DD, Postma DS, et al. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ = Journal De l’Association Medicale Canadienne. 2016;188(14):1004–1011.
   PubMed Web of Science ®Google Scholar
• Medicare And Commercial Health Insurance: The Fundamental Difference | Health Affairs. n.d. DOI:https://doi.org/10.1377/hblog20120215.016980/full/
   Google Scholar
• Regvat J, Žmitek A, Vegnuti M, et al. Anxiety and depression during hospital treatment of exacerbation of chronic obstructive pulmonary disease. J Int Med Res. 2011;39(3):1028–1038.
   PubMed Web of Science ®Google Scholar